Ziyana Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 15-11-2024
- Paid Up Capital ₹ 0.10 M
as on 15-11-2024
- Company Age 6 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 5.45%
(FY 2023)
- Profit 121.08%
(FY 2023)
- Ebitda 169.55%
(FY 2023)
- Net Worth 28.33%
(FY 2023)
- Total Assets 33.95%
(FY 2023)
About Ziyana Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Dinesh Chhabra and Mamta Chhabra serve as directors at the Company.
- CIN/LLPIN
U24304HR2018PTC072711
- Company No.
072711
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Ambala, Haryana, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Ziyana Lifesciences Private Limited offer?
Ziyana Lifesciences Private Limited offers a wide range of products and services, including Nutraceuticals & Dietary Supplements, Mineral Supplement, Digestive System Drugs & Medicines, Antacid Drugs, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Anti Infective Drugs & Medicines, Antibacterial Drugs, Muscle Relaxant, Ayurvedic,Herbal Products & Medicine.
Who are the key members and board of directors at Ziyana Lifesciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Chhabra  | Director | 23-Feb-2018 | Current |
| Mamta Chhabra | Director | 15-Sep-2020 | Current |
Financial Performance of Ziyana Lifesciences.
Ziyana Lifesciences Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 5.45% increase. The company also saw a substantial improvement in profitability, with a 121.08% increase in profit. The company's net worth Soared by an impressive increase of 28.33%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ziyana Lifesciences?
In 2023, Ziyana Lifesciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Akunoll Pharmaceuticals Private LimitedActive 2 years 9 monthsDinesh Chhabra and Mamta Chhabra are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ziyana Lifesciences?
Unlock and access historical data on people associated with Ziyana Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ziyana Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ziyana Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
